MicroRNA-Directed Biomarkers and Breast Cancer Therapeutics—Potential to Advance Personalised Approaches in Clinical Trials
International Journal of Molecular Sciences · 29.04.2026 · 27 (9) · 3996
DOI: 10.3390/ijms27093996 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 29.04.2026. Verfasst von Luis Bouz Mkabaah und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, The Lambe Institute for Translational Research, University of Galway, H91 YR71 Galway, Ireland. Hauptthemen laut MEDLINE: MicroRNAs, Biomarkers, Tumor, Breast Neoplasms, Precision Medicine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 150 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Breast Cancer Research Institute.
Abstract (Originalsprache)
The advent of breast cancer molecular subtyping has transformed management, enabling treatment personalisation and de-escalation beyond traditional stage-based approaches. Established biomarkers, such as Ki-67 in luminal disease, HER2 amplification, and PD-L1 expression in triple-negative breast cancer, underpin seminal clinical trials yet remain imperfect predictors of response and long-term outcome. MicroRNAs have emerged as promising next-generation biomarkers and therapeutic tools. As master regulators of gene expression, both tumour-derived and circulating microRNAs can refine diagnosis and molecular subclassification, inform prognosis and therapeutic selection, act as treatment sensitisers, and potentially serve as direct therapeutic targets. Well-characterised miRNAs such as miR-221 have been implicated in endocrine resistance, while recent liquid-biopsy approaches have enabled the identification of circulating miR-145 and exosomal miR-155 as predictors of pathological complete response in HER2-positive disease. Their detectability in tissue, blood and other biofluids offers a minimally invasive means to dynamically monitor cancer behaviour and response, supporting more precise therapeutic decision-making. This review synthesises the current evidence for miRNA-based biomarkers across oestrogen-receptor positive, HER2-positive and triple-negative breast cancer and outlines their potential integration into biomarker-driven clinical trial designs and personalised treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, The Lambe Institute for Translational Research, University of Galway, H91 YR71 Galway, Ireland.
- Royal College of Surgeons in Ireland, 123 St. Stephens Green, Dublin 2, D02 YN77 Dublin, Ireland.
ORCID-Profile: Luis Bouz Mkabaah, Eoin P Kerin, Eleftheria Filandrianou, Vinitha Richard
Förderung
- National Breast Cancer Research Institute
Zitieren
APA
Bouz Mkabaah, L., Kerin, E. P., Davey, M. G., Filandrianou, E., Richard, V., & Kerin, M. J. (2026). MicroRNA-Directed Biomarkers and Breast Cancer Therapeutics—Potential to Advance Personalised Approaches in Clinical Trials. International Journal of Molecular Sciences, 27(9), 3996. https://doi.org/10.3390/ijms27093996
Vancouver
Bouz Mkabaah L, Kerin EP, Davey MG, Filandrianou E, Richard V, Kerin MJ. MicroRNA-Directed Biomarkers and Breast Cancer Therapeutics—Potential to Advance Personalised Approaches in Clinical Trials. International Journal of Molecular Sciences. 2026;27(9):3996. doi:10.3390/ijms27093996
BibTeX
@article{BouzMkabaah2026,
author = {Bouz Mkabaah, Luis and Kerin, Eoin P and Davey, Matthew G and Filandrianou, Eleftheria and Richard, Vinitha and Kerin, Michael J},
title = {MicroRNA-Directed Biomarkers and Breast Cancer Therapeutics—Potential to Advance Personalised Approaches in Clinical Trials},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {9},
pages = {3996},
doi = {10.3390/ijms27093996}
}
EUVIMED